Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc Good afternoon. My name ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...

Full Year 2024 Results Key Financial Results Revenue: US$1.02b (up 22% from ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.